Search

Your search keyword '"Tiribelli, Mario"' showing total 16 results
Start Over Author "Tiribelli, Mario" Journal british journal of haematology
16 results on '"Tiribelli, Mario"'

1. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study

Author

Elli, Elena Maria, primary, Di Veroli, Ambra, additional, Bartoletti, Daniela, additional, Iurlo, Alessandra, additional, Carmosino, Ida, additional, Benevolo, Giulia, additional, Abruzzese, Elisabetta, additional, Bonifacio, Massimiliano, additional, Bergamaschi, Micaela, additional, Polverelli, Nicola, additional, Caramella, Marianna, additional, Cilloni, Daniela, additional, Tiribelli, Mario, additional, Pugliese, Novella, additional, Caocci, Giovanni, additional, Crisà, Elena, additional, Porrini, Raffaele, additional, Markovic, Uros, additional, Renso, Rossella, additional, Auteri, Giuseppe, additional, Cattaneo, Daniele, additional, Trawinska, Malgorzata Monika, additional, Scaffidi, Luigi, additional, Biale, Lucia, additional, Bucelli, Cristina, additional, Breccia, Massimo, additional, Gambacorti‐Passerini, Carlo, additional, Palumbo, Giuseppe Alberto, additional, Latagliata, Roberto, additional, and Palandri, Francesca, additional

Published
2022
Full Text
View/download PDF

2. COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report

Author

Breccia, Massimo, primary, Abruzzese, Elisabetta, additional, Accurso, Vincenzo, additional, Attolico, Immacolata, additional, Barulli, Sara, additional, Bergamaschi, Micaela, additional, Binotto, Gianni, additional, Bocchia, Monica, additional, Bonifacio, Massimiliano, additional, Caocci, Giovanni, additional, Capodanno, Isabella, additional, Castagnetti, Fausto, additional, Cavazzini, Francesco, additional, Crisà, Elena, additional, Crugnola, Monica, additional, Stella De Candia, Maria, additional, Elena, Chiara, additional, Fava, Carmen, additional, Galimberti, Sara, additional, Gozzini, Antonella, additional, Gugliotta, Gabriele, additional, Intermesoli, Tamara, additional, Iurlo, Alessandra, additional, La Barba, Gaetano, additional, Latagliata, Roberto, additional, Leonetti Crescenzi, Sabrina, additional, Levato, Luciano, additional, Loglisci, Giuseppina, additional, Lucchesi, Alessandro, additional, Luciano, Luigiana, additional, Lunghi, Francesca, additional, Luzi, Debora, additional, Malato, Alessandra, additional, Cristina Miggiano, Maria, additional, Pizzuti, Michele, additional, Pregno, Patrizia, additional, Rapezzi, Davide, additional, Rege‐Cambrin, Giovanna, additional, Rosti, Gianantonio, additional, Russo, Sabina, additional, Sancetta, Rosaria, additional, Rita Scortechini, Anna, additional, Sorà, Federica, additional, Sportoletti, Paolo, additional, Stagno, Fabio, additional, Tafuri, Agostino, additional, Tiribelli, Mario, additional, Foà, Robin, additional, and Saglio, Giuseppe, additional

Published
2021
Full Text
View/download PDF

3. Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Author

Polverelli, Nicola, primary, Elli, Elena M., additional, Abruzzese, Elisabetta, additional, Palumbo, Giuseppe A., additional, Benevolo, Giulia, additional, Tiribelli, Mario, additional, Bonifacio, Massimiliano, additional, Tieghi, Alessia, additional, Caocci, Giovanni, additional, D'Adda, Mariella, additional, Bergamaschi, Micaela, additional, Binotto, Gianni, additional, Heidel, Florian H., additional, Cavazzini, Francesco, additional, Crugnola, Monica, additional, Pugliese, Novella, additional, Bosi, Costanza, additional, Isidori, Alessandro, additional, Bartoletti, Daniela, additional, Auteri, Giuseppe, additional, Latagliata, Roberto, additional, Gandolfi, Lisa, additional, Martino, Bruno, additional, Scaffidi, Luigi, additional, Cattaneo, Daniele, additional, D’Amore, Fabio, additional, Trawinska, Malgorzata M., additional, Stella, Rossella, additional, Markovic, Uros, additional, Catani, Lucia, additional, Pane, Fabrizio, additional, Cuneo, Antonio, additional, Krampera, Mauro, additional, Semenzato, Gianpietro, additional, Lemoli, Roberto M., additional, Vianelli, Nicola, additional, Breccia, Massimo, additional, Russo, Domenico, additional, Cavo, Michele, additional, Iurlo, Alessandra, additional, and Palandri, Francesca, additional

Published
2020
Full Text
View/download PDF

6. Case–control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients

Author

Malagola, Michele, Damiani, Daniela, Martinelli, Giovanni, Michelutti, Angela, Cesana, Bruno, De Vivo, Antonio, Piccaluga, Pier Paolo, Ottaviani, Emanuela, Candoni, Anna, Geromin, Antonella, Tiribelli, Mario, Fanin, Renato, Testoni, Nicoletta, Lauria, Francesco, Bocchia, Monica, Gobbi, Marco, Pierri, Ivana, Zaccaria, Alfonso, Zuffa, Eliana, Mazza, Patrizio, Priccolo, Giancarla, Gugliotta, Luigi, Bonini, Alessandro, Visani, Giuseppe, Skert, Cristina, Bergonzi, Cesare, Roccaro, Aldo Maria, Filí, Carla, Baccarani, Michele, and Russo, Domenico

Published
2007

8. Reply to Pfirrmann and Hasford

Author

Bonifazi, Francesca, de Vivo, Antonio, Rosti, Gianantonio, Tiribelli, Mario, Russo, Domenico, Trabacchi, Elena, Fiacchini, Mauro, Montefusco, Enrico, and Baccarani, Michele

Published
2001

11. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.

Author

Polverelli, Nicola, Elli, Elena M., Abruzzese, Elisabetta, Palumbo, Giuseppe A., Benevolo, Giulia, Tiribelli, Mario, Bonifacio, Massimiliano, Tieghi, Alessia, Caocci, Giovanni, D'Adda, Mariella, Bergamaschi, Micaela, Binotto, Gianni, Heidel, Florian H., Cavazzini, Francesco, Crugnola, Monica, Pugliese, Novella, Bosi, Costanza, Isidori, Alessandro, Bartoletti, Daniela, and Auteri, Giuseppe

Subjects
SECONDARY primary cancer, MYELOFIBROSIS, SKIN cancer, MULTIVARIATE analysis
Abstract

Summary: Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non‐melanoma skin cancers (NMSCs). We analyzed the incidence, risk factors and outcome of SPMs in 700 MF patients treated with RUX in a real‐world context. Median follow‐up from starting RUX was 2·9 years. Overall, 80 (11·4%) patients developed 87 SPMs after RUX start. NMSCs were the most common SPMs (50·6% of the cases). Multivariate analysis demonstrated that male sex [hazard ratio (HR): 2·37, 95% confidence interval (95%CI): 1·22–4·60, P = 0·01] and thrombocytosis> 400 × 109/l at RUX start (HR:1·98, 95%CI: 1·10–4·60, P = 0·02) were associated with increased risk for SPMs. Risk factors for NMSC alone were male sex (HR: 3·14, 95%CI: 1·24–7·92, P = 0·02) and duration of hydroxycarbamide and RUX therapy > 5 years (HR: 3·20, 95%CI: 1·17–8·75, P = 0·02 and HR: 2·93, 95%CI: 1·39–6·17, P = 0·005 respectively). In SPMs excluding NMSCs, male sex (HR: 2·41, 95%CI: 1·11–5·25, P = 0·03), platelet > 400 × 109/l (HR: 3·30, 95%CI: 1·67–6·50, P = 0·001) and previous arterial thromboses (HR: 3·47, 95%CI: 1·48–8·14, P = 0·004) were shown to be associated with higher risk of SPMs. While it is reassuring that no aggressive lymphoma was documented, active skin surveillance is recommended in all patients and particularly after prolonged hydroxycaramide therapy; oncological screening should be triggered by thrombocytosis and arterial thrombosis, particularly in males. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

12. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

Author

Palandri, Francesca, primary, Catani, Lucia, additional, Bonifacio, Massimiliano, additional, Benevolo, Giulia, additional, Heidel, Florian, additional, Palumbo, Giuseppe A., additional, Crugnola, Monica, additional, Abruzzese, Elisabetta, additional, Bartoletti, Daniela, additional, Polverelli, Nicola, additional, Bergamaschi, Micaela, additional, Tiribelli, Mario, additional, Iurlo, Alessandra, additional, Breccia, Massimo, additional, Cavazzini, Francesco, additional, Tieghi, Alessia, additional, Binotto, Gianni, additional, Isidori, Alessandro, additional, Martino, Bruno, additional, D'Adda, Mariella, additional, Bosi, Costanza, additional, Sabattini, Elena, additional, Vitolo, Umberto, additional, Aversa, Franco, additional, Ibatici, Adalberto, additional, Lemoli, Roberto M., additional, Sgherza, Nicola, additional, Cuneo, Antonio, additional, Martinelli, Giovanni, additional, Semenzato, Giampietro, additional, Cavo, Michele, additional, Vianelli, Nicola, additional, Sapienza, Maria R., additional, and Latagliata, Roberto, additional

Published
2018
Full Text
View/download PDF

13. Case?control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients

Author

Malagola, Michele, primary, Damiani, Daniela, additional, Martinelli, Giovanni, additional, Michelutti, Angela, additional, Cesana, Bruno, additional, Vivo, Antonio De, additional, Piccaluga, Pier Paolo, additional, Ottaviani, Emanuela, additional, Candoni, Anna, additional, Geromin, Antonella, additional, Tiribelli, Mario, additional, Fanin, Renato, additional, Testoni, Nicoletta, additional, Lauria, Francesco, additional, Bocchia, Monica, additional, Gobbi, Marco, additional, Pierri, Ivana, additional, Zaccaria, Alfonso, additional, Zuffa, Eliana, additional, Mazza, Patrizio, additional, Priccolo, Giancarla, additional, Gugliotta, Luigi, additional, Bonini, Alessandro, additional, Visani, Giuseppe, additional, Skert, Cristina, additional, Bergonzi, Cesare, additional, Roccaro, Aldo Maria, additional, Filí, Carla, additional, Baccarani, Michele, additional, and Russo, Domenico, additional

Published
2007
Full Text
View/download PDF

15. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α-interferon.

Author

Bonifazi, Francesca, de Vivo, Antonio, Rosti, Gianantonio, Tiribelli, Mario, Russo, Domenico, Trabacchi, Elena, Fiacchini, Mauro, Montefusco, Enrico, and Baccarani, Michele

Subjects
LEUKEMIA treatment, MYELOID leukemia, THERAPEUTIC use of interferons, PROGNOSIS
Abstract

As it has been shown that α-interferon (αIFN) treatment modifies the survival of chronic myeloid leukaemia (CML) patients in comparison with conventional chemotherapy, a new prognostic score was devised with the aim of providing a treatment-adapted risk evaluation. We have tested the new prognostic score (the Euro score) in an independent series of 272 patients less than 56 years old with previously untreated, chronic phase, Philadelphia (Ph)-positive CML who had been assigned prospectively to αIFN treatment between 1989 and 1991. The Sokal score system was used as a reference. The new Euro score predicted the response to αIFN as the Sokal score. The median survival of low-risk, intermediate-risk and high-risk patients was similar using the Euro score (105, 65 and 45 months) and Sokal score (105, 76 and 45 months) but, by multivariate analysis, the Euro was more potent than Sokal for predicting survival time. The new Euro score identified more low-risk cases (59% vs. 48%) and fewer high-risk cases (9% vs. 23%) than the Sokal score. The main differences between the Euro and Sokal scores concerned age (it is more important in the Euro than in Sokal), spleen size and the percentage of myeloblasts in peripheral blood (more important in Sokal than in Euro). We conclude that the new Euro score marks an improvement in the prognostic evaluation of CML treated with αIFN. By comparison with the Sokal score, the Euro was more potent and identified more low-risk patients but left only a small number of cases in the high-risk group. [ABSTRACT FROM AUTHOR]

Published
2000

16. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.

Author

Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, Binotto G, Bocchia M, Bonifacio M, Caocci G, Capodanno I, Castagnetti F, Cavazzini F, Crisà E, Crugnola M, Stella De Candia M, Elena C, Fava C, Galimberti S, Gozzini A, Gugliotta G, Intermesoli T, Iurlo A, La Barba G, Latagliata R, Leonetti Crescenzi S, Levato L, Loglisci G, Lucchesi A, Luciano L, Lunghi F, Luzi D, Malato A, Cristina Miggiano M, Pizzuti M, Pregno P, Rapezzi D, Rege-Cambrin G, Rosti G, Russo S, Sancetta R, Rita Scortechini A, Sorà F, Sportoletti P, Stagno F, Tafuri A, Tiribelli M, Foà R, and Saglio G

Subjects
Aged, Disease-Free Survival, Female, Humans, Italy epidemiology, Male, Middle Aged, Retrospective Studies, Survival Rate, COVID-19 diagnosis, COVID-19 mortality, COVID-19 therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Pandemics, SARS-CoV-2
Abstract

Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results